hK6 表达与晚期胃癌肿瘤复发和预后的相关性。
Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer.
机构信息
Sun Yat-sen University, Guangzhou City, Guangdong Province, China.
出版信息
Diagn Pathol. 2013 Apr 15;8:62. doi: 10.1186/1746-1596-8-62.
BACKGROUND
Human kallikrein gene 6 (KLK6) is a member of the human kallikrein gene family (Kallikreins, KLKs). Human kallikrein-related peptidase 6 (hK6) is a trypsin-like serine protease encoded by the KLK6, has been reported to be highly expressed in several cancers including gastric cancer. In this study, we investigated the the correlation of hK6 expression with clinicopathological characteristics, tumor recurrence and prognosis in advanced gastric carcinoma after curative resection.
METHODS
We retrospectively analyzed the clinical data of 129 cases advanced gastric cancer after curative gastrectomy. The expression of hK6 in advanced gastric cancer tissues compared to adjacent noncancerous tissues were examined, and the relationship between hK6 expression and clinicopathological characteristics was evaluated. In additional, these patients were followed up to investigate the relationship between hK6 expression and the survival time.
RESULTS
The positive rate of hK6 expression was significantly higher in advanced gastric cancer tissue, than that in adjacent noncancerous and gastric ulcer tissues (36.5%, 33.3%, respectively, P < 0.001). There was a close relationship between hK6 expression and TNM stage (P = 0.005), vascular invasion (P = 0.037) and perineural invasion (P = 0.035). Furthermore, patients with hK6 positive showed significantly higher recurrence and poorer prognosis than those with hK6 negative. Multivariate analysis showed that hK6 expression was a significant independent factor for tumor recurrence and overall survival.
CONCLUSION
hK6 is overexpressed in advanced gastric cancer tissues. Its clinical utility may be used as an unfavorable indicator in predicting tumor recurrence and prognosis for advanced gastric cancer after operation. This study also suggests that hK6 might be a potential therapeutic target for gastric cancer.
VIRTUAL SLIDES
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8558403578787206.
背景
人激肽释放酶基因 6（KLK6）是人类激肽释放酶基因家族（激肽释放酶，KLKs）的成员。人激肽相关肽酶 6（hK6）是由 KLK6 编码的一种类胰蛋白酶丝氨酸蛋白酶，已被报道在包括胃癌在内的几种癌症中高度表达。在本研究中，我们研究了 hK6 表达与根治性胃切除术后晚期胃癌临床病理特征、肿瘤复发和预后的相关性。
方法
我们回顾性分析了 129 例根治性胃切除术后晚期胃癌患者的临床资料。检测了 hK6 在晚期胃癌组织中的表达，并评估了 hK6 表达与临床病理特征的关系。此外，对这些患者进行了随访，以研究 hK6 表达与生存时间的关系。
结果
hK6 表达的阳性率在晚期胃癌组织中明显高于邻近非癌组织和胃溃疡组织（分别为 36.5%、33.3%，P<0.001）。hK6 表达与 TNM 分期（P=0.005）、血管侵犯（P=0.037）和神经周围侵犯（P=0.035）密切相关。此外，hK6 阳性患者的复发率和预后明显差于 hK6 阴性患者。多因素分析显示，hK6 表达是肿瘤复发和总生存的独立显著因素。
结论
hK6 在晚期胃癌组织中过度表达。其临床应用可能作为预测术后晚期胃癌肿瘤复发和预后的不利指标。本研究还表明，hK6 可能是胃癌的潜在治疗靶点。
Zotero 插件